DailyIQ
|
Sector:HealthcareAll sectors
Last updated 40 minutes ago

ZBH·Zimmer Biomet Holdings, Inc.

$.
+. (+.%)
High
$85.68
Open
$84.82
Market Cap
16.68B
52W High
$108.29
Low
$84.10
P. Close
$84.41
P/E
21.92
52W Low
$79.12
Fwd P/E
9.38
Mean Target
$98.52
Technical Score (1D)
18
SELL
News Sentiment
57
BULLISH
Zimmer Biomet (ZBH) is being highlighted as a leading stock within the robotic surgery sector. Analysts have recently adjusted price targets, with Canaccord lowering theirs to $83 while maintaining a Buy rating, and Citizens reducing their target to $105 with an Outperform rating. The company reported solid fiscal Q1 results, which were positively impacted by early productivity gains from its US go-to-market transformation and tariff-related benefits that contributed to margin expansion. These factors led ZBH to raise its full-year EPS guidance. Investors will be watching for continued progress in the US go-to-market transformation and the sustained impact of tariff benefits on margins.
Earnings Summary
Zimmer Biomet Holdings is a global medical technology firm specializing in orthopedic and related medical devices, operating within the Medical Devices industry. The company designs, produces, and distributes solutions for musculoskeletal health, including reconstructive products for knees and hips, as well as offerings for sports medicine, trauma, and craniomaxillofacial applications. In its most recent reported quarters, Zimmer Biomet showed strong performance. For Q4 2025, the company reported actual EPS of $2.42 against an estimate of $1.91, and revenue of $2.24 billion against an estimate of $2.06 billion. This followed Q3 2025, where actual EPS was $1.90 on an estimated $1.87, with revenue of $2.00 billion. Looking at the prior two quarters, Q2 2025 saw actual EPS of $2.07 versus an estimate of $1.98, and revenue of $2.08 billion. Q1 2025 reported actual EPS of $1.81 against an estimate of $1.77, with revenue of $1.91 billion. This indicates a consistent trend of exceeding earnings expectations and strong revenue growth in recent periods. Historically, Zimmer Biomet has demonstrated a pattern of beating analyst estimates for both earnings per share and revenue across its last four reported quarters. The company has shown robust year-over-year growth, particularly in Q4 2025 where revenue significantly surpassed estimates. Recent news highlights Zimmer Biomet's management presenting at the BofA Securities Health Care Conference on May 13, 2026, providing insights into strategic initiatives. The company has also been recognized as a top growth and value stock, supported by strong fundamental performance. However, the unexpected exit of its Chief Financial Officer introduces leadership uncertainty, despite strong operational results and an upward revision of full-year guidance. For the upcoming quarter, investors will be watching for continued strong EPS and revenue performance, as well as any strategic updates from management presentations and clarity on leadership stability following the CFO's departure.

EPS

EstBeatMiss
$1.67$1.88$2.09$2.31$2.52Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.01 - -
Q4'25$1.91$2.42+26.8%
Q3'25$1.87$1.90+1.8%
Q2'25$1.98$2.07+4.8%
Q1'25$1.77$1.81+2.3%
Q4'24$2.29$2.31+0.8%

Revenue

EstBeatMiss
$1.9B$2.0B$2.1B$2.2B$2.3BQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.1B - -
Q4'25$2.1B$2.2B+9.0%
Q3'25 - $2.0B -
Q2'25 - $2.1B -
Q1'25 - $1.9B -
Q4'24 - $2.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ZBH Stock Snapshot

ZBH is currently trading at $84.93, giving Zimmer Biomet Holdings, Inc. a market cap of 16.68B and a P/E ratio of 21.9. Today's range spans $84.10–$85.68, with shares opening at $84.82 and moving up $0.52 (0.6%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 57/100.

Over the past year ZBH has traded between $79.12 and $108.29 - the current price is +7.3% off the 52-week low and -21.6% from the high. 36 analysts cover the stock with a Hold consensus and a mean 12-month target of $98.52 (range $83.00–$130.00), implying upside of +16.0%.

ZBH: large-cap, Healthcare, 16.68B market cap. (P/E: 21.9) Technical score 18/100 (SELL). Sentiment: neutral (57/100). Price: $84.93 (in the lower half of its 52-week range). Range: $79.12–$108.29. The SELL designation at this capitalization tier doesn't mean the stock is uninvestable - it means the risk/reward of buying dips hasn't been restored yet, and patience or an outright hedge is often the better posture until technical conditions improve.

When a large-cap Healthcare name with 16.68B in capitalization prints a SELL signal (18/100) alongside neutral news sentiment (57/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $84.93 (in the lower half of its 52-week range in the $79.12–$108.29 range), the structural support levels are where that sponsorship question gets answered.